Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Sermorelin crosses your target, drops, or sets a new tracked low—without daily noise.

Price scope Alert me Target per mg

$/mg

Confirmed Weekly Peptide Intel email

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.

Public product evidence 177 certificate records for Sermorelin products, from 63 vendors 102 reference a report on the testing laboratory's own system · 78 have a laboratory lookup that answered when last checked · 167 match a vendor product page at the same address

Status

Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area

GH axis / secretagogue research

Primary research area: GH axis. Also surfaces under Performance for browsing and discovery.

Aliases

Sermorelin Acetate, Geref

Signal depth

Medium

No FDA label signal · 42 trials · 34 PubMed results

Preclinical

Research evidence

Current evidence for Sermorelin is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

Sermorelin has no clinical trials that name it and 34 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data

Lab / animal only

Trial quality

No human trials

Outcomes

No human trials

Replication

Multiple papers

Literature

High-impact

The Journal of Clinical Endocrinology & Metabolism · 52 citations Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. BioDrugs · 31 citations Sermorelin Case Reports Anterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case report. Journal Article The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Journal Article Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Journal Article A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-10-03 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What sermorelin is

Sermorelin is a growth hormone-releasing hormone analogue that sits closer to the clinical side of the GH category than many generic secretagogues. It is still common in vendor listings and wellness-adjacent peptide conversations.

Why it matters

It helps bridge the gap between older hormone-therapy language and today’s research-market catalog culture.

Regulatory context

Sermorelin products widely sold through peptide vendors should be understood as unapproved retail-market offerings, not as interchangeable with any prior medical or diagnostic context.

Practical reading note

Sermorelin is a good reminder that a compound can have a more serious historical footing than the average peptide listing while still being marketed in ways that go far beyond that footing.